Table 7.
Treatment | No. pts/Eyes | % pts |
---|---|---|
Topical (CS+mydriatics) | 201/398 | 85.5 |
Intravitreal implant | 62/94 | 24.3 |
Anti-VEGF | 3/3 | 1.3 |
Sistemic CS | 203 | 86.4 |
CS+Azathioprine * | 12 | 5.1 |
CS+Methotrexate * | 29 | 12.3 |
CS+Mycophenolate M. * | 43 | 18.3 |
CS+Adalimumab * | 11 | 4.7 |
CS+Rituximab * | 3 | 1.3 |
CS+Interferon α-2a * | 4 | 1.7 |
* CS were used only in the induction phase, then slowly tapered.